Literature DB >> 11216939

Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.

P M Girard1, V Schneider, A Dehée, P Mariot, C Jacomet, N Delphin, F Damond, G Carcelain, B Autran, A G Saimot, J C Nicolas, W Rozenbaum.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11216939     DOI: 10.1097/00002030-200101260-00020

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  3 in total

1.  Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay.

Authors:  N Désiré; A Dehée; V Schneider; C Jacomet; C Goujon; P M Girard; W Rozenbaum; J C Nicolas
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort.

Authors:  C Koegl; E Wolf; N Hanhoff; H Jessen; K Schewe; M Rausch; J Goelz; A Goetzenich; H Knechten; H Jaeger; W Becker; I Becker-Boost; D Berzow; B Beiniek; J Brust; D Shcuster; S Dupke; S Fenske; H J Gellermann; R Gippert; P Hartmann; B Hintsche; H Jaeger; E Jaegel-Guedes; H Jessen; J Gölz; J Koelzsch; E B Helm; G Knecht; H Knechten; I Lochet; P Gute; S Mauruschat; S Mauss; V Miasnikov; F A Mosthaf; M Rausch; M Freiwald; B Reuter; H M Schalk; B Schappert; E Schnaitmann; I Schneider; W Schüler-Maué; C Schuler; T Seidel; W Starke; A Ulmer; M Müller; I Weitner; K Schewe; C Zamani; A Hanmond; K Ross; A Bottlaender; C Hoffmann; A Dix; A Schneidewind; M Lademann
Journal:  Eur J Med Res       Date:  2009-07-22       Impact factor: 2.175

3.  No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.

Authors:  Marlous L Grijsen; Radjin Steingrover; Ferdinand W N M Wit; Suzanne Jurriaans; Annelies Verbon; Kees Brinkman; Marchina E van der Ende; Robin Soetekouw; Frank de Wolf; Joep M A Lange; Hanneke Schuitemaker; Jan M Prins
Journal:  PLoS Med       Date:  2012-03-27       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.